EU Expansion of GSK's RSV Vaccine and Key Health News Updates

A summary of current health news includes the EU backing GSK's RSV vaccine for adults aged 50-59, rejection of Eisai and Biogen's Alzheimer’s drug, WHO's polio vaccine initiative in Gaza, EU's $2.2 billion Dutch state aid for medical isotopes, and other significant updates in the health sector.

The European Union health regulator has recommended expanding the use of GSK's respiratory syncytial virus (RSV) vaccine to adults aged 50 to 59. This decision by the European Medicines Agency's Committee for Medicinal Products for Human Use now awaits formal approval by the European Commission.

In other news, the EU’s drugs regulator has rejected the Alzheimer’s treatment Leqembi, developed by Eisai and Biogen, citing risks of serious brain swelling that outweigh its benefits. Meanwhile, the World Health Organization announced it is sending over a million polio vaccines to Gaza amid concerns over virus detection in sewage samples.

The Netherlands received EU approval for a $2.2 billion state aid package to build a nuclear reactor for producing medical isotopes, crucial for cancer treatment. Additionally, Indivior agreed to an $86 million settlement with 16 U.S. states over allegations related to opioid addiction.